Skip to main content
  • Home
  • Verve Therapeutics
Institutional profile

Verve Therapeutics

Verve Therapeutics is a clinical-stage company developing genetic medicines for cardiovascular disease; Eli Lilly and Company completed its acquisition on 25 July 2025. Its inclusion reflects an operating platform that is active, institutionally visible, and sufficiently developed to be assessed alongside other consequential participants in cell & Gene Therapy Developers.

  • Highest 2026 tier: Tier III
  • Cell & Gene Therapy Developers
  • 1 ranking category

Overview

Verve Therapeutics is a clinical-stage company developing genetic medicines for cardiovascular disease; Eli Lilly and Company completed its acquisition on 25 July 2025. Its inclusion reflects an operating platform that is active, institutionally visible, and sufficiently developed to be assessed alongside other consequential participants in cell & Gene Therapy Developers.

Within this category, the important distinction is not scale alone. Buyers, patients, health systems, life-sciences sponsors, clinicians, or institutional partners—depending on the service—also need evidence of specialist depth, delivery infrastructure, governance, geographic reach, and the ability to support demanding use cases over time. Verve Therapeutics contributes a credible combination of these characteristics.

Published assessment: Top 30 Cell & Gene Therapy Developers 2026 — Verve Therapeutics.

Firm facts

Public identityVerve Therapeutics
Institution typeCell & Gene Therapy Developers institution
Primary focusCell & Gene Therapy Developers
Highest 2026 ranking tierTier III

Activities in published assessments

Top 30 Cell & Gene Therapy Developers 2026 — Verve Therapeutics

Verve Therapeutics is a clinical-stage company developing genetic medicines for cardiovascular disease; Eli Lilly and Company completed its acquisition on 25 July 2025. Its inclusion reflects an operating platform that is active, institutionally visible, and sufficiently developed to be assessed alongside other consequential participants in cell & Gene Therapy Developers.

Within this category, the important distinction is not scale alone. Buyers, patients, health systems, life-sciences sponsors, clinicians, or institutional partners—depending on the service—also need evidence of specialist depth, delivery infrastructure, governance, geographic reach, and the ability to support demanding use cases over time. Verve Therapeutics contributes a credible combination of these characteristics.

Principal activities

Verve Therapeutics is assessed using public institutional information and category-specific editorial research.

Core capability

Cell & Gene Therapy Developers

Client relevance

Category-specific capability, institutional credibility and the ability to support demanding professional, commercial or patient needs.

Execution and verification

Current service scope, leadership, geographic coverage, legal entities and regulated activities should be confirmed directly.

Sector and mandate coverage

Primary category

Cell & Gene Therapy Developers

Institutional context

Coverage reflects the institution’s role in the ranking categories listed below. Precise services, products, jurisdictions, clinical scope and client eligibility should be verified for each use case.

Market position

Verve Therapeutics is assessed using public institutional information and category-specific editorial research.

Verve Therapeutics is assessed through public institutional information and Ranking News editorial research. Its strongest 2026 result is Tier III.

Competitive context

The relevant peer set varies by category, geography, client segment and mandate. Verve Therapeutics should be compared on current category-specific capability, senior involvement, evidence of comparable work, operating resilience and any applicable regulatory or clinical permissions.

Comparable institutions are shown for navigation and market context. Inclusion does not imply identical scale, ownership, geographic coverage, service model or regulatory status.

Leadership and governance

Leadership, ownership, governance and senior-team responsibilities may change. Current information should be verified through authoritative institutional sources.

Corporate and public information

The public-facing organization is identified here as Verve Therapeutics. Contracting entities, regulated affiliates, clinical operations, offices and legal permissions may differ by service and jurisdiction.

Corporate and disclosure information
OrganizationVerve Therapeutics
Verification noteConfirm legal entity, licenses, offices and engagement terms directly before appointment or use.

Rankings and recognition

2026

Tier III

Ranking inclusion and tier classification are editorial determinations. They should be read as category-specific assessments rather than universal league-table positions. The existence or maintenance of this Wiki profile does not influence ranking eligibility, tier or position.

Related Economy analysis

Selected reporting and market analysis from The Economy provides context for the institution’s operating environment:

Sources and data transparency

Official institutional information, where available, is used for current public identity and capabilities. Ranking pages document 2026 category and tier status. Economy articles provide market context rather than institution-specific endorsement.

  1. Healthcare Ranking — Top 30 Cell & Gene Therapy Developers 2026 — 2026 inclusion and tier classification.
  2. The Economy — Healthcare Rankings and the New Economics of Expertise — market context.
  3. The Economy — Healthcare Market Structure Is Opening a New Lane for Specialist Providers — market context.
  4. The Economy — Healthcare Rankings and the New Geography of Distributed Care — market context.

Corrections and Updates

Factual corrections, updated institutional information, and supporting references may be submitted through The Economy Portal. All proposed changes are subject to editorial verification before publication.

First published: 29 August 2026

Last substantively reviewed: 29 August 2026

Profile scope: Cell & Gene Therapy Developers

This profile has been compiled from publicly available institutional and editorial sources. The profiled organization does not determine its inclusion, editorial characterization or ranking status.